ADC Therapeutics
UEI: VFJLCNLYZNB3
• CAGE: SJTV9
Overview
Awardee Type
Parent
(1 child)
Company Description
Learn about ADC Therapeutics, a commercial-stage oncology biotechnology company, leading the development of next-generation antibody drug conjugates (ADCs).
Name
ADC Therapeutics
Headquarters
Epalinges, VD
Switzerland
Switzerland
Most Recent Award
Sept. 29, 2025
Calculating
Federal contract recipient
ADC THERAPEUTICS SA
(UEI VFJLCNLYZNB3, CAGE SJTV9)
is headquartered in Epalinges VD.
Its primary registered NAICS is 325412 Pharmaceutical Preparation Manufacturing.
The corporation
was founded in June 2011 and
federally registered in
September 2020.
Federal Award Analysis
ADC Therapeutics federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
Legal Name
ADC THERAPEUTICS SA
Division Name
ADC THERAPEUTICS SA & ADC THERAPEUTICS USA
Division Number
ADC THERAP
UEI
VFJLCNLYZNB3
CAGE Code
SJTV9
Primary NAICS
SBA Certifications
None
Self Certifications
None
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
June 6, 2011
Initial Registration
Sept. 29, 2020
Last Registration
Dec. 18, 2021
Registration Activation
Dec. 21, 2020
Registration Expiration
Dec. 18, 2021
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
Manufacturer of Goods
Manufacturer of Goods
Country of Incorporation
CHE
Employees
<500
Reported NAICS
Accepts Credit Cards
No
People
Vendor contacts at ADC Therapeutics
GSA Schedules and Price Lists
- ADC Therapeutics America
- PoP: 9/30/21 - 9/30/26
- Type: Pharmaceuticals and Drugs (FSS 65 I B)
- ADC Therapeutics America
- PoP: 6/17/21 - 10/14/21 (Ended)